戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lacement might prove beneficial for treating mucopolysaccharidoses.
2 ies of ASB and GALNS are associated with the mucopolysaccharidoses.
3 treating CNS storage diseases, including the mucopolysaccharidoses.
4 isease, Fabry disease, Pompe disease and the mucopolysaccharidoses.
5 wo disease groups: glycosphingolipidoses and mucopolysaccharidoses.
6 of anakinra in Sanfilippo syndrome and other mucopolysaccharidoses.
7 g for use in substrate reduction therapy for mucopolysaccharidoses, a group of inherited metabolic di
8 biochemical and pathological features of the mucopolysaccharidoses and particularly features of mucop
9 yme replacement therapy for fucosidosis, the mucopolysaccharidoses, and neuronal ceroid lipofuscinosi
10 kodystrophy, GM1 and GM2 gangliosidosis, the mucopolysaccharidoses, and neuronal ceroid lipofuscinosi
11                                              Mucopolysaccharidoses are a group of genetically inherit
12                                          The mucopolysaccharidoses are caused by inherited deficienci
13                                              Mucopolysaccharidoses are inherited metabolic disorders
14 and beta- mannosidosis, fucosidosis, and the mucopolysaccharidoses; enzyme replacement therapy for fu
15 e replacement therapy has been used to treat mucopolysaccharidoses; however, neuropathology has remai
16 ers such as metachromatic leukodystrophy and mucopolysaccharidoses IIIA.
17 tandard therapeutic option for some types of mucopolysaccharidoses, including Morquio A syndrome caus
18 , pathologic and biochemical features of the mucopolysaccharidoses, lysosomal storage diseases caused
19                                          The mucopolysaccharidoses (MPS) are a family of lysosomal st
20                                          The mucopolysaccharidoses (MPS) are LSDs defined by the stor
21                                          The mucopolysaccharidoses (MPS) are lysosomal storage disord
22                                          The mucopolysaccharidoses (MPS) are rare genetic disorders m
23 glycan (GAG) storage in animal models of the mucopolysaccharidoses (MPS) leads to inflammation and ap
24  biomarkers that accumulate in patients with mucopolysaccharidoses (MPS), a subclass of lysosomal sto
25 sult in lysosomal storage disorders known as mucopolysaccharidoses (MPS), causing severe pathology, p
26 henylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn
27 eneic off-the-shelf cell therapy for several mucopolysaccharidoses (MPS).
28 ber of diseases, most notably several of the mucopolysaccharidoses (MPS).
29                                          The mucopolysaccharidoses (MPSs) are a class of inborn error
30                                          The mucopolysaccharidoses (MPSs) are a complex family of lys
31                                              Mucopolysaccharidoses (MPSs) are childhood diseases caus
32                                              Mucopolysaccharidoses (MPSs) are lysosomal storage disea
33                                          The mucopolysaccharidoses (MPSs) are lysosomal storage disea
34 rapy is currently available for three of the mucopolysaccharidoses (MPSs) but has limited effects on
35 bclass of lysosomal storage disorders called mucopolysaccharidoses (MPSs), many of which present with
36     Sanfilippo disease describes a subset of mucopolysaccharidoses resulting from defects in heparan
37  (CLN1 or CLN2 deficiency, respectively) and mucopolysaccharidoses type VII (MPS VII), a deficiency o
38 us systemic diseases, such as hemophilia and mucopolysaccharidoses types I and VII, has encountered s
39 teoglycans beyond their association with the mucopolysaccharidoses, we modified the expression of ASB